Menu Search
Equities

Strata Skin Sciences Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
E2O:FRA

Strata Skin Sciences Inc

Actions
  • Price (EUR)3.76
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta0.3129
Data delayed at least 15 minutes, as of Jun 06 2024 08:02 BST.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

STRATA Skin Sciences, Inc. is a medical technology company in dermatology. The Company is engaged in developing, commercializing and marketing products for the treatment of dermatologic conditions. The Company operates through two segments: Dermatology Recurring Procedures and Dermatology Procedures Equipment. The Company’s products include the XTRAC and Pharos excimer lasers and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its products also include the TheraClear Acne Therapy System utilized in the treatment of mild to moderate inflammatory, comedonal and pustular acne. The XTRAC and Pharos excimer laser technology emits highly concentrated ultraviolet (UV) light targeted primarily towards autoimmune dermatological skin disorders, such as psoriasis, vitiligo, atopic dermatitis, and eczema, among others. VTRAC is a UV light lamp system that works in much the same way as the XTRAC.

  • Revenue in USD (TTM)30.98m
  • Net income in USD-11.04m
  • Incorporated1997
  • Employees106.00
  • Location
    Strata Skin Sciences Inc5 Walnut Grove Drive, Suite 140HORSHAM 19044United StatesUSA
  • Phone+1 (215) 619-3200
  • Fax+1 (215) 619-3209
  • Websitehttps://www.strataskinsciences.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.